Moreover, recent evidence suggests that nintedanib can boost the efficacy of immunotherapy by upregulating MHC-I and PD-L1 expression and increasing the infiltration of CD8+ T cells and DC cell maturation to enhance tumor sensitivity to immunotherapy in both in vivo and in vitro experiments (45, 46), which warrants further clinical evaluation. Here, CD274 is linked to neoplasm.